SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
228.9 EUR
-0.1 (-0.04%)
We assign a fundamental rating of 3 out of 10 to SRT3. SRT3 was compared to 20 industry peers in the Life Sciences Tools & Services industry. SRT3 has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SRT3 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
In the past 5 years SRT3 has always been profitable.
SRT3 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SRT3 (1.04%) is worse than 80.00% of its industry peers.
Looking at the Return On Equity, with a value of 3.92%, SRT3 is doing worse than 80.00% of the companies in the same industry.
The Return On Invested Capital of SRT3 (3.80%) is worse than 70.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SRT3 is in line with the industry average of 7.27%.
The 3 year average ROIC (8.34%) for SRT3 is well above the current ROIC(3.80%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROIC | 3.8% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
SRT3 has a Profit Margin of 3.00%. This is in the lower half of the industry: SRT3 underperforms 75.00% of its industry peers.
In the last couple of years the Profit Margin of SRT3 has declined.
SRT3's Operating Margin of 12.48% is on the low side compared to the rest of the industry. SRT3 is outperformed by 65.00% of its industry peers.
In the last couple of years the Operating Margin of SRT3 has declined.
With a decent Gross Margin value of 45.76%, SRT3 is doing good in the industry, outperforming 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
SRT3 has more shares outstanding than it did 1 year ago.
SRT3 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRT3 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.30 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.30, SRT3 is in line with its industry, outperforming 45.00% of the companies in the same industry.
The Debt to FCF ratio of SRT3 is 8.09, which is on the high side as it means it would take SRT3, 8.09 years of fcf income to pay off all of its debts.
SRT3 has a Debt to FCF ratio of 8.09. This is in the lower half of the industry: SRT3 underperforms 70.00% of its industry peers.
A Debt/Equity ratio of 1.54 is on the high side and indicates that SRT3 has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.54, SRT3 is doing worse than 85.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Altman-Z | 2.3 |
ROIC/WACC0.5
WACC7.53%
2.3 Liquidity
A Current Ratio of 1.39 indicates that SRT3 should not have too much problems paying its short term obligations.
SRT3 has a Current ratio of 1.39. This is in the lower half of the industry: SRT3 underperforms 65.00% of its industry peers.
A Quick Ratio of 0.88 indicates that SRT3 may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.88, SRT3 is doing worse than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.21% over the past year.
SRT3 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -11.87% yearly.
SRT3 shows a small growth in Revenue. In the last year, the Revenue has grown by 3.80%.
SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
3.2 Future
Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.16% on average per year.
SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.92% yearly.
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 52.62, the valuation of SRT3 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 80.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.86, SRT3 is valued quite expensively.
Based on the Price/Forward Earnings ratio of 38.40, the valuation of SRT3 can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 80.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, SRT3 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.62 | ||
| Fwd PE | 38.4 |
4.2 Price Multiples
70.00% of the companies in the same industry are cheaper than SRT3, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRT3 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.79 | ||
| EV/EBITDA | 24.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRT3's earnings are expected to grow with 22.38% in the coming years.
PEG (NY)2.26
PEG (5Y)N/A
EPS Next 2Y20.61%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
With a yearly dividend of 0.41%, SRT3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.71, SRT3 has a dividend in line with its industry peers.
With a Dividend Yield of 0.41, SRT3 pays less dividend than the S&P500 average, which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 48.70% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.7%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
FRA:SRT3 (10/6/2025, 12:11:27 PM)
228.9
-0.1 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.14B
Analysts80
Price Target314.94 (37.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.33%
Min EPS beat(2)-10.52%
Max EPS beat(2)-4.13%
EPS beat(4)0
Avg EPS beat(4)-10.28%
Min EPS beat(4)-22.4%
Max EPS beat(4)-4.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.97%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.92%
PT rev (3m)-12.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.25%
EPS NY rev (1m)0.59%
EPS NY rev (3m)0.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.15%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.62 | ||
| Fwd PE | 38.4 | ||
| P/S | 4.94 | ||
| P/FCF | 29.79 | ||
| P/OCF | 18.65 | ||
| P/B | 6.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.41 |
EPS(TTM)4.35
EY1.9%
EPS(NY)5.96
Fwd EY2.6%
FCF(TTM)7.68
FCFY3.36%
OCF(TTM)12.27
OCFY5.36%
SpS46.31
BVpS35.5
TBVpS-35.06
PEG (NY)2.26
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROCE | 5.11% | ||
| ROIC | 3.8% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 13.6% | ||
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% | ||
| FCFM | 16.59% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 80.56% | ||
| Cap/Sales | 9.91% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 552.64% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.3 |
F-Score7
WACC7.53%
ROIC/WACC0.5
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
EBIT growth 1Y1.03%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.49%
FCF growth 1Y187.94%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y14.51%
OCF growth 3Y4.07%
OCF growth 5Y20.79%